Heparin-induced skin lesions

Summary Cutaneous reactions to subcutaneous heparin injections have been described first in 1952. These reactions may be caused by several mechanisms such as immediate or delayed-type hypersensitivity responses, or by life-threatening immune-mediated heparin-induced thrombocytopenia (HIT). In contrast to bleeding, induction of osteoporosis and hair loss, no data on the incidence and causes of heparin-induced skin lesions had been available until recently. In a large prospective epidemiological study, the incidence of heparin-induced skin lesions was as high as 7.5% in medical patients, far exceeding the expected incidence. As heparin-induced skin lesions may be the sole clinical manifestation of immune HIT, rapid and valid diagnosis of heparin-induced skin lesions is of utmost clinical importance. Therefore, we have reviewed all known causes of heparin-induced skin lesions, and propose diagnostic and therapeutic procedures.

[1]  T. Warkentin.  Clinical picture of heparin-induced thrombocytopenia , 2012 .

[2]  J. Asencio,et al.  Dabigatran offers the simplest solution for thromboprophylaxis after orthopaedic surgery in patients allergic to low‐molecular‐weight heparins , 2010, British journal of haematology.

[3]  I. Marzi,et al.  Low allergenic potential with fondaparinux: results of a prospective investigation. , 2010, Mayo Clinic proceedings.

[4]  T. Warkentin,et al.  Non‐necrotizing heparin‐induced skin lesions and the 4T’s score , 2010, Journal of thrombosis and haemostasis : JTH.

[5]  H. Ackermann,et al.  Heparin‐induced non‐necrotizing skin lesions: rarely associated with heparin‐induced thrombocytopenia , 2010, Journal of thrombosis and haemostasis : JTH.

[6]  M. Schön,et al.  Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. , 2010, Blood.

[7]  H. Büller,et al.  Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. , 2010, The New England journal of medicine.

[8]  N. Brousse,et al.  Calcinosis cutis: a rare reaction to subcutaneous injections of calcium-containing heparin in patients with renal failure. , 2010, The American Journal of dermatopathology.

[9]  R. Ludwig.  Therapeutic use of heparin beyond anticoagulation. , 2009, Current drug discovery technologies.

[10]  D. Salameire,et al.  Calcinose cutanée et sous-cutanée après injection d’héparine calcique : à propos de deux cas , 2009 .

[11]  M. Schindewolf,et al.  Incidence and causes of heparin-induced skin lesions , 2009, Canadian Medical Association Journal.

[12]  B. Gersh,et al.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial , 2009, The Lancet.

[13]  M. Andréjak,et al.  Dermatose bulleuse hémorragique associée à une réaction d’hypersensibilité retardée sous héparine de bas poids moléculaire ☆ , 2009 .

[14]  L. Cerroni,et al.  Intraepidermal bullous haemorrhage during anticoagulation with low‐molecular‐weight heparin: two cases , 2009, The British journal of dermatology.

[15]  J. Pfeilschifter,et al.  PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions. , 2009, The Journal of investigative dermatology.

[16]  M. Röcken,et al.  Mast cells: novel clinical perspectives from recent insights , 2009, Experimental dermatology.

[17]  S. Palmer,et al.  Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. , 2009, American heart journal.

[18]  M. Kneilling,et al.  Recall urticaria induced by skin tests with heparin , 2009, The British journal of dermatology.

[19]  H. Uncu.  A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis , 2009, Phlebology.

[20]  M. Torres,et al.  Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins , 2009, The British journal of dermatology.

[21]  Miguel Park,et al.  Successful Heparin Desensitization: A Case Report and Review of the Literature , 2008, Journal of cardiac surgery.

[22]  M. Schindewolf,et al.  Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. (Thromb Haemost 2008; 99: 779–781) , 2008, Thrombosis and Haemostasis.

[23]  R. Langer,et al.  Contaminated heparin associated with adverse clinical events and activation of the contact system. , 2008, The New England journal of medicine.

[24]  J. Hirsh,et al.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[25]  A. Lincoff,et al.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[26]  J. Hirsh,et al.  Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[27]  G. Guyatt,et al.  Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[28]  M. Schindewolf,et al.  The influence of heparin’s molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514–17 , 2008, The British journal of dermatology.

[29]  M. Schindewolf,et al.  Tolerance of fondaparinux in patients with generalized contact dermatitis to heparin , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[30]  W. Aberer,et al.  Acute generalized exanthematous pustulosis from dalteparin. , 2007, Journal of the American Academy of Dermatology.

[31]  W. Aberer,et al.  Delayed‐type hypersensitivity to low molecular weight heparins and heparinoids: cross‐reactivity does not depend on molecular weight , 2007, The British journal of dermatology.

[32]  W. Pichler,et al.  Delayed drug hypersensitivity reactions – new concepts , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[33]  Sarabjeet Singh,et al.  Enoxaparin-induced skin necrosis: a fatal outcome. , 2007, American journal of therapeutics.

[34]  W. Aberer,et al.  Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Commentary. , 2007 .

[35]  T. Treasure,et al.  Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance , 2007, BMJ : British Medical Journal.

[36]  E. Lindhoff-Last,et al.  Danaparoid in der Schwangerschaft bei Heparinunverträglichkeit , 2007, Hämostaseologie.

[37]  C. Francis.  Prophylaxis for Thromboembolism in Hospitalized Medical Patients , 2007 .

[38]  R. Zotz,et al.  Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids , 2007, Thrombosis and Haemostasis.

[39]  A. Bircher,et al.  Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options , 2006, Allergy.

[40]  T. Kohlmann,et al.  Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. , 2006, Blood.

[41]  U. Jappe.  Allergy to heparins and anticoagulants with a similar pharmacological profile: an update , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[42]  J. Utikal,et al.  Management of cutaneous type IV hypersensitivity reactions induced by heparin , 2006, Thrombosis and Haemostasis.

[43]  W. Boehncke,et al.  Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. , 2006, Mini reviews in medicinal chemistry.

[44]  Y. Mazor,et al.  A fatal case of enoxaparin induced skin necrosis and thrombophilia , 2006, European journal of haematology.

[45]  E. Hachulla,et al.  Use of low-molecular-weight heparin from the first trimester of pregnancy: a retrospective study of 111 consecutive pregnancies. , 2006, European journal of obstetrics, gynecology, and reproductive biology.

[46]  D. W. Hawkins,et al.  Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. , 2006, Cardiovascular drug reviews.

[47]  A. Bircher,et al.  Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux , 2006, Allergy.

[48]  B. White,et al.  Low‐molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor‐κB in LPS‐stimulated human monocytes , 2006, British journal of haematology.

[49]  C. Sigouin,et al.  Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings , 2006, Journal of thrombosis and haemostasis : JTH.

[50]  R. Henschler,et al.  The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo , 2006, Thrombosis and Haemostasis.

[51]  L. Machet,et al.  Bullous hemorrhagic dermatosis occurring at sites distant from subcutaneous injections of heparin: three cases. , 2006, Journal of the American Academy of Dermatology.

[52]  M. Prins,et al.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.

[53]  M. Schindewolf,et al.  Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides , 2005, Thrombosis and Haemostasis.

[54]  B. A. Muller,et al.  Heparin allergy: successful desensitization for cardiopulmonary bypass. , 2005, The Journal of thoracic and cardiovascular surgery.

[55]  P. Wells,et al.  Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. , 2005, Blood.

[56]  D. Massi,et al.  Iatrogenic calcinosis cutis following nadroparin injection , 2005, International journal of dermatology.

[57]  M Gent,et al.  Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high‐risk abdominal surgery , 2005, The British journal of surgery.

[58]  A. Varki,et al.  Differential Metastasis Inhibition by Clinically Relevant Levels of Heparins—Correlation with Selectin Inhibition, Not Antithrombotic Activity , 2005, Clinical Cancer Research.

[59]  L. Borradori,et al.  Calcifying panniculitis following subcutaneous injections of nadroparin‐calcium in a patient with osteomalacia , 2005, The British journal of dermatology.

[60]  I. Greer,et al.  Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. , 2005, Blood.

[61]  T. Kohlmann,et al.  Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis , 2005, Thrombosis and Haemostasis.

[62]  J. Hirsh,et al.  Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. , 2005, Chest.

[63]  S Alban,et al.  From heparins to factor Xa inhibitors and beyond , 2005, European journal of clinical investigation.

[64]  S. Hoerstrup,et al.  Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro , 2005, The British journal of surgery.

[65]  E. Bröcker,et al.  Tolerance to intravenous heparin in patients with delayed‐type hypersensitivity to heparins: a prospective study , 2005, British journal of haematology.

[66]  B. Brenner,et al.  Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE‐ENOX study , 2005, Journal of thrombosis and haemostasis : JTH.

[67]  S. Middeldorp,et al.  Skin reactions due to low molecular weight heparin in pregnancy: a strategic dilemma , 2005, Archives of Gynecology and Obstetrics.

[68]  L. Schwartz,et al.  Heparin‐induced recurrent anaphylaxis , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[69]  C. Campbell,et al.  Delayed‐type hypersensitivity to subcutaneous heparin with tolerance of i.v. administration , 2004, ANZ journal of surgery.

[70]  Richard M Martin,et al.  Allergic reactions to enoxaparin and heparin: a case report and review of the literature. , 2004, The New Zealand medical journal.

[71]  A. Greinacher,et al.  Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[72]  Michael Thomas,et al.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  C. Dempfle.  Minor transplacental passage of fondaparinux in vivo. , 2004, The New England journal of medicine.

[74]  R. Henschler,et al.  Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. , 2004, Cancer research.

[75]  C. Dempfle,et al.  Akral betonte Hautnekrosen , 2004, Der Hautarzt.

[76]  T. Krieg,et al.  Calcinosis of the cutis and subcutis: an unusual nonimmunologic adverse reaction to subcutaneous injections of low-molecular-weight calcium-containing heparins. , 2004, Journal of the American Academy of Dermatology.

[77]  A. Greinacher,et al.  Treatment of Heparin-Induced Thrombocytopenia: An Overview , 2003 .

[78]  P. Demoly,et al.  Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations , 2003, Allergy.

[79]  W. Boehncke,et al.  Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans , 2003, Contact dermatitis.

[80]  H. Büller,et al.  High rate of skin complications due to low‐molecular‐weight heparins in pregnant women , 2003, Journal of thrombosis and haemostasis : JTH.

[81]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial , 2002, The Lancet.

[82]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison , 2002, The Lancet.

[83]  C. Vergnes,et al.  Absence of Placental Transfer of Pentasaccharide (Fondaparinux, Arixtra®) in the Dually Perfused Human Cotyledon in vitro , 2002, Thrombosis and Haemostasis.

[84]  M. Poncz,et al.  Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. , 2002, Blood.

[85]  E. Racine,et al.  Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. , 2002, Seminars in thrombosis and hemostasis.

[86]  K. Smith,et al.  Delayed cutaneous hypersensitivity reactions to hirudin. , 2001, Archives of pathology & laboratory medicine.

[87]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. , 2001, The New England journal of medicine.

[88]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. , 2001, The New England journal of medicine.

[89]  J. Kelton,et al.  Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis , 2001, Annals of Internal Medicine.

[90]  A. Taylor.  Successful use of heparinoids in a pregnancy complicated by allergy to heparin , 2001, BJOG : an international journal of obstetrics and gynaecology.

[91]  David R. Nadeau,et al.  Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[92]  D. Ruiter,et al.  Nadroparin-Induced Calcinosis cutis in Renal Transplant Recipients , 2001, Nephron.

[93]  A. Daud,et al.  Anticoagulant and Antiprotease Effects of a Novel Heparinlike Compound From Shrimp (Penaeus brasiliensis) and Its Neutralization by Heparinase I , 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[94]  P. Fritsch,et al.  Delayed‐Type Hypersensitivity and Cross‐Reactivity to Heparins and Danaparoid: A Prospective Study , 2001, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[95]  P. Koch,et al.  Delayed allergic skin reactions to subcutaneous heparins. Tolerance of 2 recombinant hirudins. , 2000, Contact dermatitis.

[96]  P. Koch,et al.  Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin. , 2000, Journal of the American Academy of Dermatology.

[97]  M. Stephenson,et al.  Low‐Molecular‐Weight Heparins in Pregnancy , 1999, Pharmacotherapy.

[98]  C. Bayerl,et al.  Association of heparin‐induced skin lesions, intracutaneous tests, and heparin‐induced IgG , 1999, Allergy.

[99]  B. Brenner,et al.  Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review , 1999, Thrombosis and Haemostasis.

[100]  A. Trautmann,et al.  Intravenous challenge with heparins in patients with delayed‐type skin reactions after subcutaneous administration of the drug , 1998, Contact Dermatitis.

[101]  R. Aster,et al.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. , 1998, Blood.

[102]  B. Nair,et al.  Heparin-induced skin lesions. , 1998, Australian and New Zealand journal of medicine.

[103]  J. Kelton,et al.  A 14-year study of heparin-induced thrombocytopenia. , 1996, The American journal of medicine.

[104]  C. Ojukwu,et al.  Deep vein thrombosis in pregnancy and heparin hypersensitivity , 1996, British journal of obstetrics and gynaecology.

[105]  W. Boehncke,et al.  Tolerance to intravenous admiration of heparin and heparinoid in a patient with delayed‐type hypersensitivity to heparins and heparinoids , 1996, Contact dermatitis.

[106]  L. Laroche,et al.  [Toxic dermatitis caused by heparin]. , 1996, Presse medicale.

[107]  K. Wolff,et al.  Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro. , 1996, Journal of immunology.

[108]  D. F. Fayed,et al.  Successful heparin desensitization after heparin-induced anaphylactic shock. , 1995, Thrombosis research.

[109]  A. Greinacher,et al.  Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-associated Thrombocytopenia , 1995, Thrombosis and Haemostasis.

[110]  L. V. Staker,et al.  Delayed Hypersensitivity Reaction to Heparin in a Pregnant Woman , 1995, International journal of dermatology.

[111]  P. Itin,et al.  Delayed hypersensitivity to one low‐molecular‐weight heparin with tolerance of other low‐molecular‐weight heparins , 1995, The British journal of dermatology.

[112]  V. Hach-Wunderle,et al.  Heparin-associated thrombosis despite normal platelet counts. , 1994, Lancet.

[113]  E. Lemarié,et al.  Subcutaneous heparin treatment increases survival in small cell lung cancer , 1994, Cancer.

[114]  P. Itin,et al.  Skin lesions, hypereosinophilia, and subcutaneous heparin , 1994, The Lancet.

[115]  D. Schiavino,et al.  Rush desensitization in heparin hypersensitivity: a case report , 1994, Allergy.

[116]  A. Greinacher,et al.  Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. , 1994, Thrombosis and haemostasis.

[117]  M. Petitou,et al.  The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics , 1993 .

[118]  F. Raimondo,et al.  Hypereosinophilia and subcutaneous heparin , 1993, The Lancet.

[119]  T. Ahmed,et al.  Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. , 1993, The New England journal of medicine.

[120]  B. Hunt,et al.  Heparin‐induced skin reaction due to two different preparations of low molecular weight heparin (LMWH) , 1993, British journal of haematology.

[121]  P. Koch,et al.  Tolerance of intravenous low‐molecular‐weight heparin after eczematous reaction to subcutaneous heparin , 1991, Contact dermatitis.

[122]  S. Kumar,et al.  Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin. , 1989, Journal of cardiothoracic anesthesia.

[123]  A. Leung.  Toxic epidermal necrolysis associated with maternal use of heparin. , 1985, Journal of the American Medical Association (JAMA).

[124]  A. Pollock,et al.  Skin necrosis after heparin injection. , 1981, British medical journal.

[125]  S. Pitlik,et al.  HYPERSENSITIVITY REACTION TO CHLORBUTOL-PRESERVED HEPARIN , 1981, The Lancet.

[126]  T. Barrowcliffe,et al.  Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. , 1976, Thrombosis research.

[127]  King Fa.  OSTEOPOROSIS, FRACTURES, AND HEPARIN THERAPY. , 1965 .

[128]  I. Bernstein.  Anaphylaxis to heparin sodium; report of a case, with immunologic studies. , 1956, Journal of the American Medical Association.

[129]  E. Jorpes.  On the chemistry of heparin. , 1935, The Biochemical journal.

[130]  M. Schindewolf,et al.  Diagnosis of heparin-induced delayed type hypersensitivity , 2010, Phlebologie.

[131]  J. Bazin,et al.  Heparin-induced skin necrosis: HIT-2 without thrombocytopenia , 2010, Intensive Care Medicine.

[132]  B. Chong,et al.  Heparin-induced thrombocytopenia associated with fondaparinux. , 2007, The New England journal of medicine.

[133]  C. Lok,et al.  [Low-molecular-weight heparin-induced bullous haemorrhagic dermatosis associated with cell-mediated hypersensitivity]. , 2009, Annales de dermatologie et de venereologie.

[134]  A. Greinacher,et al.  Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. , 2009, Expert opinion on drug safety.

[135]  C. Francis.  Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. , 2007, The New England journal of medicine.

[136]  Z. Caliskaner,et al.  Recurrent urticaria lesions in a heparin-allergic patient: most likely another form of "recall urticaria". , 2005, Journal of investigational allergology & clinical immunology.

[137]  E. Ohman,et al.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.

[138]  W. Stolz,et al.  Tolerance of desirudin in a patient with generalized eczema after intravenous challenge with heparin and a delayed-type skin reaction to high and low molecular weight heparins and heparinoids. , 2000, Contact dermatitis.

[139]  A. Greinacher,et al.  Antigen Generation in Heparin-Associated Thrombocytopenia: The Nonimmunologic Type and the Immunologic Type Are Closely Linked in Their Pathogenesis , 1995, Seminars in thrombosis and hemostasis.

[140]  J. M. Osborne,et al.  The Fc Receptor for Immunoglobulin G (FcγRII) on Human Platelets , 1995, Seminars in thrombosis and hemostasis.

[141]  J. Scott,et al.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. , 1994, The Journal of clinical investigation.

[142]  F. Kingery.  OSTEOPOROSIS, FRACTURES, AND HEPARIN THERAPY. , 1965, Journal of the American Medical Association (JAMA).